

21 October 2022

Mad Paws Holdings (MPA)

BUY

Share Price: A\$0.13

Purring its way to EBITDA break-even in mid-CY23

MPA's 1Q23 results and commentary suggest that the company remains on-track to report positive operating EBITDA by mid-CY23 (i.e., 1H24). While our forecasts are unchanged, we remain impressed by MPA's sales trajectory and operating leverage to date and expect this growth to continue, underpinned by its first-mover advantage becoming more entrenched. Reiterate Buy.

Positive momentum continues in 1Q23

- MPA has confirmed another strong quarter, with 1Q23 sales up 301% on pcp to \$5.4m. While both segments made positive contributions relative to pcp, eCommerce & Subscription was the key driver during the period.
- MPA was able to convert the strong sales growth to incremental EBITDA, with the 1Q23 operating loss falling to \$1.4m, from \$2.2m in pcp and \$1.8m in 4Q22, due primarily to lower (i.e., -8%) CACs.
- Marketplace was the key driver of operating leverage despite a lower incremental sales contribution, reporting a sequential margin gain of 11% to 20%, versus the 6% margin gain to -22% for eCommerce & Subscription.
- While operating cash outflows were broadly consistent with 4Q22, higher capex and lease costs more than offset the benefit from lower WC, with this translating to net cash of \$3.5m, down from \$5.6m in 4Q22.

On-track for break-even by mid-CY23

- While still early days from a market penetration point-ofview, MPA's progress to date has been positive, with Marketplace having now delivered two consecutive quarters of positive operating EBITDA.
- Having optimised Dinner Bowl and initiated a companywide re-branding programme to enhance cross-sales and lower CACs, we remain confident that MPA can transition to positive operating EBITDA by mid-CY23.

Earnings forecasts unchanged

Our earnings forecasts are unchanged and consistent with MPA's (i) annualised revenue for FY23, based on a quarterly run rate of ~20%, and (ii) target to transition to positive operating EBITDA by mid-CY23.

Reiterate Buy rating and \$0.30ps TP

- Solid growth in Mad Paws' customer base over the last five years, combined with the continued execution of its growth strategy suggests that the company is on-track to become a key participant in the pet services market.
- Based on our earnings estimates and DCF analysis, we derive a fair value estimate of \$0.30 per MPA share. This equates to an FY23 EV/revenue multiple of 3.3x, which is reasonable given our forecast growth profile.

Target Price: A\$0.30

Company Data	
Shares – ordinary (M)	321.6
Dilution (M)	7.0
Total (fully diluted) (M)	328.6
Market capitalisation (\$M)	40.2
12-month low/high (\$)	0.11 - 0.26
Average monthly turnover (\$M)	0.1
GICS Industry	Internet & Direct Marketing Retail

Financial Summary (fully diluted/normalised)

Year End June	2021A	2022A	2023F	2024F	2025F
Revenue (A\$m)	2.9	9.8	28.0	42.0	52.4
Costs (A\$m)	14.4	19.6	31.7	40.2	47.4
EBITDA (A\$m)	-11.6	-9.7	-3.7	1.8	5.0
NPAT (A\$m)	-11.9	-10.3	-4.1	1.3	4.6
EPS (¢)	-9.9	-3.7	-1.3	0.4	1.4
EPS Growth (%)	-100.0	62.7	65.9	+100.0	+100.0
PER (x)	NM	NM	NM	30.5	8.8
FCF (A\$m)	-3.8	-6.6	-2.2	4.0	6.7
FCF per share (cps)	-3.2	-2.4	-0.7	1.2	2.1
Price to FCF (x)	-3.9	-5.3	-18.4	10.2	6.1
EV (A\$m)	16.2	35.7	38.3	34.6	28.2
EV/EBITDA	-1.4	-3.5	-9.2	25.7	6.1
Payout ratio (%)	0.0	0.0	0.0	0.0	0.0
Dividend (¢)	0.0	0.0	0.0	0.0	0.0
Net Yield (%)	0.0	0.0	0.0	0.0	0.0
Franking (%)	0.0	0.0	0.0	0.0	0.0



Disclosure and Disclaimer

This report must be read with the disclosure and disclaimer on the final page of this document. Petra Capital was joint lead manager and bookrunner for this Company's placement of shares to raise \$5.6m at \$0.18/sh on 21 February 2022, for which a fee was received.

> James Lennon +61 2 9239 9618



0.0

0.0

4.1

(0.1)

(0.3)

(0.3)

4.0

0.0

0.0

(0.1)

(0.1)

3.7

Mar-22

2025F

52.4

5.0

0.5

4.6

(0.0)

0.0

4.6

(0.0)

0.0

4.6 0.0

4.6

2025F

24.7

+100.0

+100.0

+100.0

+100.0

0.0

2025F

13.0

3.1

5.2

0.7

22.2

0.2

20.4

2.9 23.6

45.7

16.8

0.2

5.3

22.3

23.4

23.4

0.0

23.4

328.6

2025F

5.0

1.7

0.1

0.0

0.0

6.8

(0.1)

(0.3)

(0.3)

6.7

0.0

0.0


(0.1)

(0.1)

6.4

Analysis

Mad Paws											
Year End June											
MARKET DATA							12-MONTH SHARE PRICE PERFO	RMANCE			
Recommendation						Buy	140 ¬				
Price	\$					0.13	140				
Price target (12-month)	\$					0.30	120 -	_	· Mrs.	Appl	
52 week high / low	\$				0	.11 - 0.26	100	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	Aprilan	mart	~~~/~~
Market capitalisation	\$m					40.2	80 My Mar Mar	۰ . I	•		V V
Shares on issue (basic)	no.					321.6	80 -	· Mm rW			
Options	no.					7.0		10			- MPA
•							60 -				
Other equity	no.					0.0	40				
Shares on issue (diluted)	no.					328.6		Jul-21 S	ep-21	Nov-21	J
NVESTMENT FUNDAMENTALS		2021A	2022A	2023F	2024F	2025F	PROFIT AND LOSS		2021A	2022A	2023F
Reported net profit	\$m	(11.9)	(10.3)	(4.1)	1.3	4.6	Total revenue	\$m	2.9	9.8	28.0
Underlying net profit	\$m	(11.9)	(10.3)	(4.1)	1.3	4.6	EBITDA	\$m	(11.6)	(9.7)	(3.7)
Underlying NPATA	\$m	(11.9)	(10.3)	(4.1)	1.3	4.6	Depreciation & amortisation	\$m	0.2	0.6	0.4
							EBIT	\$m	(11.8)	(10.3)	(4.1)
Reported EPS (diluted)	¢	(9.9)	(3.7)	(1.3)	0.4	1.4	Net interest	\$m	0.1	0.0	(0.0)
Underlying EPS (diluted)	¢	(9.9)	(3.7)	(1.3)	0.4	1.4	Non-operating income	\$m	0.0	0.0	0.0
Growth	%	-100.0	62.7	65.9	+100.0	+100.0	Pretax Profit	\$m	(11.9)	(10.4)	(4.1)
Underlying PER (diluted)	x	NM	NM	NM	30.5	8.8	Tax expense *	\$m	0.0	(0.0)	0.0
chaony ng r En (unated)	^	14141	14161	14141	50.5	0.0	Minorities	\$m	0.0	0.0	0.0
Operating cash flow per share	¢	(3.1)	(2.3)	(0.7)	1.2	2.1	Underlying NPAT	\$m	(11.9)	(10.3)	(4.1)
Free cash flow per share	¢	(3.1)	(2.3)	(0.7)	1.2	2.1	Significant items	şm \$m	0.0	0.0	(4.1)
		• •	• •	• •			•		-		
Price to free cash flow per share	x	(3.9)	(5.3)	(18.4)	10.2	6.1	Reported NPAT	\$m	(11.9)	(10.3)	(4.1)
Free cash flow yield	%	(25.4)	(18.8)	(5.4)	9.8	16.4	GROWTH PROFILE		2021A	2022A	2023F
Dividend per share	¢	0.0	0.0	0.0	0.0	0.0	Operating revenue	%	42.8	244.2	184.5
Payout ratio	%	0.0	0.0	0.0	0.0	0.0	EBITDA	%	-100.0	15.8	62.0
field	%	0.0	0.0	0.0	0.0	0.0	EBIT	%	-100.0	12.4	59.9
	%	0.0	0.0	0.0	0.0	0.0		%	-100.0	12.4	60.1
Franking	70	0.0	0.0	0.0	0.0	0.0	Underlying NPAT				
	•	40.5	<u></u>				Underlying EPS	%	-100.0	62.7	65.9
Enterprise value	\$m	16.2	35.7	38.3	34.6	28.2	DPS	%	0.0	0.0	0.0
EV/EBIT	х	(1.4)	(3.5)	(9.2)	25.7	6.1					
Price to book (NAV)	х	2.6	1.8	2.3	2.2	1.8	BALANCE SHEET		2021A	2022A	2023F
Price to NTA	х	2.6	(97.3)	(8.9)	(12.7)	28.7	Cash	\$m	12.5	5.6	3.0
							Receivables	\$m	0.1	0.2	1.7
KEY RATIOS		2021A	2022A	2023F	2024F	2025F	Inventory	\$m	0.2	0.9	2.8
EBITDA margin	%	(404.9)	(99.1)	(13.2)	4.3	9.6	Other	\$m	0.4	0.7	0.7
EBIT margin	%	(413.6)	(105.3)	(14.8)	3.2	8.8	Current	\$m	13.2	7.4	8.2
Underlying net profit margin	%	(418.1)	(105.3)	(14.8)	3.2	8.8	Prop, plant & equip	\$m	0.1	0.2	0.2
Return on average equity	%	(158.7)	(58.2)	(21.1)	7.4	21.9	Goodwill	\$m	2.8	20.4	20.4
Return on average assets	%	(124.0)	(43.3)	(13.2)	3.9	11.0	Other	\$m	0.8	2.8	2.8
		, -/	(7	(Non current	\$m	3.7	23.5	23.5
Net tangible assets per share	¢	4.7	(0.1)	(1.4)	(1.0)	0.4	Total assets	\$m	16.8	30.9	31.7
Net debt /(cash)	۴ \$m	(12.5)	(5.4)	(2.8)	(6.5)	(12.8)	Accounts Payable	\$m	1.3	4.1	8.9
nterest cover (EBIT / net interest)	X	(92.1)	(300.5)	(2.0) n/a	128.9	(12.0) n/a	Borrowings	\$m	0.0	0.2	0.3
(/		. ,	. ,	n/a	120.9 n/a		Other	şin \$m	1.5	5.0	5.1
Leverage (net debt / EBIT)	X 0/	n/a	n/a			n/a					
Gearing (net debt / equity)	%	n/a	n/a	n/a	n/a	n/a	Total liabilities	\$m	2.9	9.3	14.2
							Net assets	\$m	14.0	21.6	17.5
DUPONT ANALYSIS		2021A	2022A	2023F	2024F	2025F	Equity	\$m	14.0	21.6	17.5
Vet Profit Margin	%	(418.1)	(105.3)	(14.8)	3.2	8.8	Minorities	\$m	0.0	0.0	0.0
Asset Turnover	х	0.3	0.4	0.9	1.2	1.3	Shareholder's equity	\$m	14.0	21.6	17.5
Return on Assets	%	(125.3)	(43.3)	(13.2)	3.9	11.1					
Financial Leverage	х	1.3	1.3	1.6	1.9	2.0	Shares on issue	m	218.5	318.1	321.6
Return on Equity	%	(158.7)	(58.2)	(21.1)	7.4	21.9					
CASH FLOW SUMMARY							CASH FLOW EBITDA	¢	2021A	2022A	2023F
								\$m \$m	(5.0)	(8.3)	(3.7)
\$10m -							Change in working capital	\$m	0.7	2.0	1.5
							Net interest	\$m	0.0	(0.0)	0.1



Source: Petra Capital

Tax paid *

Operating cash flow

Acquisitions/divestment/other

Increase / (decrease) in borrowings

Capital expenditure

Investing cash flow

Financing cash flow

Free cash flow

Dividend/other

Net cash flow

Other

Equity

\$m

0.0

0.5

(3.7)

(0.1)

(1.3)

(1.3)

(3.8)

16.6

0.0

(0.0)

16.6

11.5

(0.0)

(0.0)

(6.4)

(0.2)

(6.1)

(6.3)

(6.6)

5.9

(0.1)

(0.1)

5.8

(6.9)

0.0

0.0

(2.2)

(0.1)

(0.3)

(0.3)

(2.2)

0.0

0.0

(0.1)

(0.1)

(2.6)



Petra Capital

Level 17, 14 Martin Place, Sydney NSW 2000

Director:	George Marias	+61 (0)2 9239 9601	gmarias@petracapital.com.au
Research (Resources):	Brett McKay	+61 (0)2 9239 9605	bmckay@petracapital.com.au
Research (Resources):	Hugh Stackpool	+61 (0)2 9239 9625	hstackpool@petracapital.com.au
Research (Resources):	David Brennan	+61 (0)2 9239 9630	dbrennan@petracapital.com.au
Research (Resources):	Andrew Harrington	+61 (0)2 9239 9614	aharrington@petracapital.com.au
Research (Resources):	Kieran Barratt	+61 (0)2 9239 9610	kbarratt@petracapital.com.au
Research (Resources):	Colin McLelland	+61 (0)2 9239 9639	cmclelland@petracapital.com.au
Research (Resources):	Craig Campbel	+61 (0)402 135 410	ccampbell@petracapital.com.au
Research (Industrials):	Sam Haddad	+61 (0)2 9239 9633	shaddad@petracapital.com.au
Research (Industrials):	Ken Wagner	+61 (0)2 9239 9642	kwagner@petracapital.com.au
Research (Industrials):	Daniel Ireland	+61 (0)2 9239 9642	direland@petracapital.com.au
· · · · · · · · · · · · · · · · · · ·	Mark Yarwood	+61 (0)2 9239 9646	
Research (Industrials):	Tanushree Jain	+61 (0)2 9239 9649	myarwood@petracapital.com.au
Research (Healthcare): Sales:	Frank Barila		tjain@petracapital.com.au
Sales: Sales:	Vincent Pisani	+61 (0)2 9239 9603	fbarila@petracapital.com.au
		+61 (0)2 9239 9617	vpisani@petracapital.com.au
Sales:	Peter Veldhuizen	+61 (0)2 9239 9609	pveldhuizen@petracapital.com.au
Sales:	Neil Watson	+61 (0)2 9239 9602	nwatson@petracapital.com.au
Sales:	Leigh Gardner	+61 (0)2 9239 9620	lgardner@petracapital.com.au
Sales:	Vince Barila	+61 (0)2 9239 9627	vbarila@petracapital.com.au
Sales:	Colin Redmond	+61 (0)2 9239 9613	credmond@petracapital.com.au
Sales:	Richard Macphillamy	+61 (0)2 9239 9604	rmacphillamy@petracapital.com.au
Sales:	Paul Doherty	+61 (0)407 194 549	pdoherty@petracapital.com.au
Sales:	Tyrone Lara	+61 (0)2 9239 9608	tlara@petracapital.com.au
Sales:	Vince Musumeci	+61 (0)2 9239 9606	vmusumeci@petracapital.com.au
Sales:	Andrew Richards	+61 (0)2 9239 9638	arichards@petracapital.com.au
Sales:	Rob Dobson	+61 (0)2 9239 9628	rdobson@petracapital.com.au
Sales:	Denise Wong	+61 (0)2 9239 9650	dwong@petracapital.com.au
Corporate (ECM):	Verity Barritt	+61 (0)2 9239 9622	vbarritt@petracapital.com.au
Administration:	Belinda Teichmann	+61 (0)2 9239 9636	bteichmann@petracapital.com.au
Administration:	Joanne Condopoulos	+61 (0)2 9239 9635	jcondopoulos@petracapital.com.au
Administration:	Victoria Smith	+61 (0)2 9239 9616	vsmith@petracapital.com.au
Administration:	Katya Beidar	+61 (0)2 9239 9645	kbeidar@petracapital.com.au
Administration:	Lacinda Browne	+61 (0)2 9239 9624	lbrowne@petracapital.com.au
Administration:	Larissa Falvo	+61 (0)2 9239 9611	lfalvo@petracapital.com.au
Administration:	Emma Pagalday	+61 (0)2 9239 9621	epagalday@petracapital.com.au
Legal & Compliance:	Danielle Smith	+61 (0)2 9239 9612	dsmith@petracapital.com.au
Financials:	Tony Christelis	+61 (0)2 9239 9615	tchristelis@petracapital.com.au

Disclosure

This document has been prepared in Australia by Petra Capital Pty Ltd which holds an Australian Financial Services License AFSL 317 944. Petra Capital Pty Ltd is an ASX and Chi-X Market Participant. Petra Capital Pty Ltd and its associates, officers, directors, employees and agents, from time to time, may receive brokerage, commissions, fees or other benefits or advantages, hold securities in companies researched by Petra Capital Pty Ltd and may trade in these securities either as principal or agent. Petra Capital was joint lead manager and bookrunner for this Company's placement of shares to raise \$5.6m at \$0.18/sh on 21 February 2022, for which a fee was received.

Disclaimer

The information or advice contained in this report has been obtained from sources that were accurate at the time of issue, however the information has not been independently verified and as such, Petra Capital Pty Ltd cannot warrant its accuracy or reliability. Persons relying on this information do so at their own risk. To the extent permitted by law, Petra Capital Pty Ltd disclaims all liability or responsibility for any direct or indirect loss or damage (including consequential loss or damage) caused by any error or omission within this report, or by persons relying on the contents of this report.

This report is published by Petra Capital Pty Ltd by way of general information or advice only. This report does not take into account specific investment needs or other considerations that may be pertinent to individual investors. Before making any investment decisions based on this report, parties should consider, with or without an investor adviser, whether any relevant part of this report is appropriate to their financial circumstances and investment objectives. Petra Capital Pty Ltd is a licensed institutional/wholesale stockbroking firm. The report is only intended for institutional and sophisticated clients to whom Petra Capital Pty Ltd has issued the report. Petra Capital Pty Ltd is not licensed to advise retail investors – retail investors should contact their own stockbroker or financial adviser/planner for advice.

Ratings

Information regarding the scope and expertise of our research services, processes for selection for coverage, and the management of conflicts of interest can be found on Petra Capital's website at <u>http://www.petracapital.com.au/research-disclosures</u>. Petra Capital uses the following ratings system and definitions: Buy - Forecast to re-rate by more than 5% in 12 months; Hold - Forecast to perform up to 5% above or below the current market price in 12 months, or alternatively, where a share price exceeds Petra Capital's valuation but there is a belief that business growth opportunities or commodity price moves, may result in material valuation and share price upside within 12 months; Sell - Forecast to underperform by more than 5% in 12 months; Speculative Buy - Speculative Investment; Take Profits - Recommend taking short term profits in a stock we remain fundamentally positive on a medium term view; Accept Offer - For a company under takeover where we see the offer as a fair price with low risk of a competing offer; No Rating - No rating at this time.

US Investors

This material is intended for use in the US only by major US Institutional Investors, as that term is defined by the SEC Rule 15a-6. Transactions with US Institutional Investors and major US Institutional Investors, as those terms are defined by SEC Rule 15a-6, are chaperoned by Global Alliance Securities, LLC, ("Global Alliance"), a SEC-registered broker-dealer and FINRA member (web: www.globalaliancescourities, com) in accordance with the agreement between Global Alliance and Petra Capital Pty Ltd. The information on which this material is based was obtained from sources believed to be reliable but has not been independently verified. Therefore, its accuracy is not guaranteed. Additional and supporting information is available upon request. This is not an offer or solicitation of an offer to buy or sell any security or to make any investment. Any opinion or estimate constitutes the preparer's best judgement as of the date of preparation and is subject to change without notice. Petra Capital Pty Ltd or Global Alliance and their associates or affiliates, and their respective officers, directors and employees may buy or sell securities mentioned herein as agent or principal for their own account.

Other International

International investors are encouraged to contact their local regulatory authorities to determine whether restrictions apply in buying/selling this investment.

21 October 2022

ABN 95 110 952 782 ACN 110 952 782 AFSL 317 944